MDT-AP-3334
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 6.8
- sex
- M
- new_clusters
- S2
- umap1_2d
- -0.207837735
- umap2_2d
- -8.874477071
- umap1_3d
- -3.742839918
- umap2_3d
- -2.093086847
- umap3_3d
- 6.73090734
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.530
- MYC_TARGETS_V1+0.530
- MYC_TARGETS_V2+0.510
- E2F_TARGETS+0.500
- MITOTIC_SPINDLE+0.400
- UV_RESPONSE_DN+0.280
- APICAL_SURFACE+0.250
- MTORC1_SIGNALING+0.250
- PROTEIN_SECRETION+0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.410
- INTERFERON_GAMMA_RESPONSE-0.260
- COAGULATION-0.230
- P53_PATHWAY-0.220
- TNFA_SIGNALING_VIA_NFKB-0.220
- XENOBIOTIC_METABOLISM-0.210
- COMPLEMENT-0.190
- IL6_JAK_STAT3_SIGNALING-0.190
- KRAS_SIGNALING_DN-0.190
- INFLAMMATORY_RESPONSE-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG257 | — | — | 0.860 |
| 2 | ERR2598185 | fetal | fetal | 0.860 |
| 3 | MNG753 | — | — | 0.853 |
| 4 | DF749F48-6A86-4640-9C62-31B4A7C5D1A9 | — | — | 0.853 |
| 5 | ERR2598180 | fetal | fetal | 0.851 |
| 6 | MDT-AP-3308 | Med | Medulloblastoma | 0.841 |
| 7 | BS_4SCWT0FX | EPN | EPN Tumor | 0.840 |
| 8 | BS_Z7890YNR | EPN | Supratentorial EPN | 0.839 |
| 9 | A3153235-3128-40AC-9371-AFA1F61E3E59 | — | — | 0.838 |
| 10 | MNG1168 | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |